Natera Study Shows High PPV for NIPT; Company Looks Toward Low-risk Market, Cancer Testing | GenomeWeb

NEW YORK (GenomeWeb) – Close on the heels of research that highlighted how widely the reported specificity and the positive predictive value of sequencing-based non-invasive prenatal tests can diverge, Natera, one of several companies offering clinical sequencing-based NIPT, has published a study of its Panorama test showing high PPV not only for higher-risk but also lower-risk women.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.